Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance Schedules in Follicular Lymphoma
NCT00227695Phase 3Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2004
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Event-Free Survival at 10 years. Started Jun 2004; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00227695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227695.